Analysts Set Expectations for Actinium Pharmaceuticals, Inc.’s Q1 2023 Earnings (NYSEAMERICAN:ATNM)

Posted by Defense World Staff on Apr 7th, 2023

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Rating) – Equities researchers at HC Wainwright issued their Q1 2023 earnings per share (EPS) estimates for Actinium Pharmaceuticals in a research note issued to investors on Monday, April 3rd. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will earn ($0.40) per share for the quarter. HC Wainwright has a “Buy” rating and a $53.00 price target on the stock. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.68) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q2 2023 earnings at ($0.42) EPS, Q3 2023 earnings at ($0.39) EPS, Q4 2023 earnings at ($0.43) EPS, FY2023 earnings at ($1.66) EPS and FY2024 earnings at ($1.14) EPS.

ATNM has been the topic of a number of other reports. William Blair lowered Actinium Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Tuesday, February 21st. Cantor Fitzgerald increased their price target on Actinium Pharmaceuticals from $26.00 to $27.00 in a research report on Tuesday. Finally, StockNews.com lowered Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, March 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $33.25.

Actinium Pharmaceuticals Stock Up 3.1 %

Shares of NYSEAMERICAN:ATNM opened at $8.98 on Thursday. Actinium Pharmaceuticals has a twelve month low of $4.67 and a twelve month high of $15.12. The stock’s 50 day moving average is $10.89 and its 200-day moving average is $10.21. The firm has a market capitalization of $231.06 million, a price-to-earnings ratio of -6.60 and a beta of 0.39.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) last issued its quarterly earnings results on Monday, April 3rd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.01). Actinium Pharmaceuticals had a negative net margin of 2,885.09% and a negative return on equity of 41.64%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in Actinium Pharmaceuticals by 1.1% in the 1st quarter. BlackRock Inc. now owns 230,950 shares of the biotechnology company’s stock worth $1,180,000 after purchasing an additional 2,618 shares during the period. Blair William & Co. IL boosted its stake in Actinium Pharmaceuticals by 15.8% in the 1st quarter. Blair William & Co. IL now owns 100,566 shares of the biotechnology company’s stock worth $514,000 after purchasing an additional 13,700 shares during the period. State Street Corp boosted its stake in Actinium Pharmaceuticals by 12.5% in the 1st quarter. State Street Corp now owns 63,015 shares of the biotechnology company’s stock worth $322,000 after purchasing an additional 7,023 shares during the period. Renaissance Technologies LLC bought a new position in Actinium Pharmaceuticals in the 2nd quarter worth about $278,000. Finally, Virtu Financial LLC boosted its stake in Actinium Pharmaceuticals by 154.0% in the 2nd quarter. Virtu Financial LLC now owns 35,789 shares of the biotechnology company’s stock worth $172,000 after purchasing an additional 21,699 shares during the period. Institutional investors own 11.23% of the company’s stock.

Actinium Pharmaceuticals Company Profile

(Get Rating)

Actinium Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engages in the development of novel targeted therapies known as Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. The company was founded in 2000 and is headquartered in New York, NY.